About Therabron

This author has not yet filled in any details.
So far Therabron has created 11 blog entries.

Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.

Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367, Indicated for the Treatment of Bronchiolitis Obliterans Syndrome. For more information please click here.

By |January 24th, 2017|Recent News|

Therabron Therapeutics to Present at the 2016 Biotech Showcase Conference

ROCKVILLE, MD, January 7, 2016 – Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to redefining the management of respiratory disease through innovation, today announced that its President and Chief Executive Officer, […]

By |January 7th, 2016|Uncategorized|

Therabron Therapeutics Makes Strategic Changes and Expands Management Team

ROCKVILLE, MD, December 10, 2015 — Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced new appointments and changes to the Company’s management […]

By |December 10th, 2015|Recent News|

Therabron Therapeutics Announces Favorable Infant Outcomes with Six-Month Follow-Up of a Phase 1b Recombinant Human CC10 Clinical Trial

ROCKVILLE, MD, December 8, 2015 — Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory care, today presented a retrospective analysis of long-term follow-up data from […]

By |December 8th, 2015|Recent News|

Therabron Therapeutics Receives Accelerated Second Tranche from Series B Financing and Expands Investor Syndicate

ROCKVILLE, MD – November 9, 2015 – Therabron Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing a new standard in respiratory care, today announced that the Company has received an accelerated […]

By |November 11th, 2015|Recent News|

Therabron Therapeutics to Participate in Upcoming Healthcare Conferences

ROCKVILLE, MD, October 15, 2015 – Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to redefining the management of respiratory disease through innovation, today announced that it will participate in two […]

By |November 3rd, 2015|Recent News|

Therabron Therapeutics Reaches 50 Percent Enrollment in Phase 2 Clinical Trial for Lead Pediatric Respiratory Critical Care Program

ROCKVILLE, MD, July 21, 2015  — Therabron Therapeutics, Inc., a specialty biotechnology company dedicated to redefining the management of respiratory disease through innovation, today announced that it has achieved over […]

By |July 21st, 2015|Recent News|

Therabron Therapeutics Secures New Orphan Designation for the Prevention of Bronchopulmonary Dysplasia

ROCKVILLE, MD — May 13, 2015 — Therabron Therapeutics, Inc. (Therabron), a specialty biotechnology company focused on the advancement of respiratory therapeutics with disease-modifying potential, today announced that the European […]

By |May 13th, 2015|Recent News|

Therabron Therapeutics Names Thomas F. Miller President and Chief Operating Officer

ROCKVILLE, MD, May 7, 2015 — Therabron Therapeutics, Inc. (Therabron), a specialty biotechnology company focused on the advancement of respiratory therapeutics with disease-modifying potential, announced that it has named Thomas […]

By |May 7th, 2015|Recent News|

Therabron Therapeutics, Inc. Secures Up to $11M in Series B Financing

Rockville, MD. – December 17, 2014 – www.therabron.com a privately held clinical-stage biotechnology company, today announced that it has secured an investment of up to $11.1M in multiple tranches […]

By |December 17th, 2014|Recent News|